Clinical development for ATMPs looks deceptively familiar on the surface. There’s still a protocol, a dose escalation plan, safety monitoring, endpoints, and data review. But once you get into the details, the differences become impossible to ignore. Variability in starting materials, patient specific biology, long-term follow-up, and the potential for irreversible effects all shape how these studies must be designed and run. But once you get into the details, the differences become impossible to ignore. Variability in starting materials, patient specific biology, long term follow up, and the potential for irreversible effects all shape how these studies must be designed and run.
For early phase sponsors, the most common challenges aren’t scientific — they’re structural. They come from overlooking practical realities, underestimating operational demands, or applying small molecule thinking to a modality that behaves nothing like one. This checklist brings together the ten essentials that consistently determine whether an ATMP clinical programme moves smoothly or runs into avoidable friction.
ATMPs often begin with donor or patient derived material, and that variability carries through to the clinic. Release specifications, viability, and consistency all influence how the product behaves once administered. Teams that understand this early will design protocols that reflect the real world behaviour of their product. Release specifications, viability, and consistency all influence how the product behaves once administered. Teams that understand this early design protocols that reflect the real world behaviour of their product.
ATMPs rarely leave much material to spare. Retention samples, stability considerations, and the need for reconfirmation all require careful planning. Sampling strategies must be realistic, justified, and aligned with the product’s characteristics.
Traceability, coding, processing, storage, and transport aren’t administrative details — they’re regulatory expectations. ATMPs demand a level of documentation and control that goes beyond standard clinical trial logistics.
Biopsies and cell collection procedures can affect safety, product quality, and even eligibility. These steps need clear justification, robust risk mitigation, and investigator training that reflects the sensitivity of the process, as collection procedures can affect safety, product quality, and even eligibility. These steps need clear justification, robust risk mitigation, and investigator training that reflects the sensitivity of the process.
ATMPs often require specialised preparation, thawing, or bedside procedures. Every step — from storage to disposal — must be defined, validated, and taught. A single deviation can compromise the product or the patient.
Repeat dosing, dose escalation, and dose justification all look different for ATMPs. Biological activity, not milligrams, drives decision-making. Sponsors must be ready to explain how dose was chosen and how it will be adapted as data emerge. Sponsors must be ready to explain how dose was chosen and how it will be adapted as data emerge.
Previous therapies, infections, vaccinations, and immune status can all influence how an ATMP behaves. These factors need to be built into eligibility criteria, safety monitoring, and data interpretation.
ATMPs can have durable — and sometimes irreversible — effects. Sponsors must consider not only the patient, but close contacts, future pregnancies, and long-term health. This isn’t optional; it’s central to the benefit–risk assessment.
Regulators expect structured, multiyear follow-up for many ATMPs. Investigators must be trained, systems must be in place, and patients must understand what long-term participation entails ¬yearly follow ups for many ATMPs. Investigators must be trained, systems must be in place, and patients must understand what long term participation entails.
ATMPs often combine a biological component with a device, a procedure, or both. When adverse events occur, causality must be assessed across all components — including administration, concomitant medications, and product performance. This requires a framework that is defined before the first patient is dosed.
An early phase specialist ecosystem elevates ATMP clinical work clinical science, clinical operations, and regulatory strategy. When these functions operate in isolation, the gaps show quickly — a sampling plan that doesn’t match CMC realities, eligibility criteria that ignore non clinical signals, or a follow up plan that doesn’t satisfy regulators. phase specialist ecosystem brings these disciplines together. It ensures that clinical design reflects the biology of the product, that operational plans match the demands of the therapy, and that regulatory expectations are met without unnecessary rework. For sponsors, this integration turns a complex clinical pathway into one that feels structured, supported, and predictable.
ATMP clinical development isn’t defined by complexity — it’s defined by specificity. Teams that understand the unique demands of these therapies, and who build their studies around those realities, move forward with fewer surprises and stronger data.